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1. Introduction
Coronaviruses (CoVs) are a group of viruses named 
after their crown-shaped spike proteins. Coronaviruses 
are known for infecting a broad range of classes in the 
Animalia kingdom, including humans, mice, snakes, 
and other vertebrates [37]. Till the mid-1960s only six 
human coronaviruses were known HCoV-229E, HCoV-
-OC43, HCoV-NL63, HCoV-HKU1s, severe acute 
respiratory syndrome coronavirus (SARS-CoV), and 
Middle East respiratory syndrome coronavirus (MERS-
-CoV) [29, 30]. These six HCoVs can be divided into 
two groups based on the severity of the infection they 
cause. Group A includes HCoV-229E, HCoV-OC43, 
HCoV-NL63, and HCoV-HKU1 usually causes a less 
virulent disease, in one study HCoV-229E and HCoV-
-OC43 accounted for 15–29% of the respiratory patho-
gen with low virulence for humans [29, 30].
Group B includes SARS-CoV and MERS-CoV. These 
two have different pathogenicity but have a high fatality 
rate when compared to other members of coronaviruses. 
MERS-CoV caused renal failure and acute pneumonia 
in its first patient from Saudi Arabia in 2012. That virus 
infected 2494 people with 858  deaths reported from 
27 countries with a case fatality rate (CFR) of 34.4%. 
SARS-CoV caused respiratory failure in patients fir-
stly recognized and reported from China and infected 
8422 people with 919 deaths from 32 countries between 
November 2012 and August 2013 with CFR of 11% [41]. 
Emerging at the end of 2019 in Wuhan, China, 
SARS-CoV-2 was initially recognized as a pneumonia-
-causing unknown agent related to coronavirus, after 
which it was declared as a Public Health Emergency by 
WHO on 30 January 2020. On 11 February 2020 WHO 
officially declared the name “COVID-19” for this novel 
coronavirus disease [13]. It has become an international 
calamity affecting over 32.1 million people worldwide 
with over 980,000 deaths overall and these numbers are 
still increasing day by day [38]. The countries severely 
affected by COVID-19 included the USA, India, Brazil, 
Russia, France, Italy, China, Spain, Germany, and in 
short the rest of the world, however, the highest deaths 
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are being reported from the USA, India, Italy, France, 
Spain, and UK [39]. The new variant SARS-CoV-2 
causes severe acute respiratory syndrome and leads to 
death [26]. On 22 April, CFR worldwide of COVID-19 
is calculated to be 6.89% [39] compared to on March 3 
was 3.4% [38]. However, if we take account of mor-
tality rate between different countries for example, 
in Italy the virus has a mortality rate of 7.2% vs 2.1% 
in China. According to current information, the sugge-
sted source of SARS-CoV-2 is likely bats (it is normally 
host to many CoVs), but there is no absolute evidence 
on its origin [2].
Coronaviruses have been known for years since 
the 1960s but how long they had existed is not known. 
Commonly they cause mild disease, but some highly 
pathogenic strains do occur that are noted by being 
given a distinct name after causing an outbreak. 
COVID-19 is the current pandemic the whole world 
is fighting. The pathogenesis of this novel virus is still 
unclear. In this article, we aim to discuss the transmis-
sion, pandemic, genetic diversity, and antiviral treat-
ments, and precautionary measures against COVID-19. 
2. Pathogenesis of coronaviruses
CoVs enters a human body when coming in contact 
with a source animal, or infected human body fluids 
via sneezing droplets, coughing, sharing food, touch-
ing virus soiled inanimate objects, etc. In the case of 
SARS-CoV2, the virus will bind to Angiotensin con-
verting enzyme 2 (ACE2) in the lower respiratory tract 
of an infected individual using its spike (S) proteins [9, 
10]. For SARS-CoV, only single stranded (ss) positive 
sense RNA genome is released inside the cytoplasm of 
8a Present Absent
8b 84 amino acids 121 amino acids
3b 154 amino acids 22 amino acids
Table I
The differences found in proteins of SARS-CoV and SARS-CoV-2
Protein SARS-CoV SARS-CoV-2
Fig. 1. The structure of SARS-CoV-2. ssRNA genome (26–32 kb) in 
the center, four structural proteins: spike glycoprotein (S), envelope 
protein (E), matrix protein (M), and nucleocapsid protein (N). Apart 
from these, many accessory proteins are also present but not shown 
in the figure [22].
a cell through fusion between a host cell’s membrane 
and the virus [28]. But the same entry mechanism used 
by SARS-CoV-2 still needs to be confirmed. Once 
inside the cell ss+RNA act as mRNA and the host ribo-
some initiates translation of viral proteins: two polypro-
teins and structural protein (NS and S) which help in 
viral genomic replication and capsid formation [23]. 
Newly formed envelope glycoprotein migrate to the 
Golgi apparatus or Endoplasmic reticulum (not shown 
in figure 2), after which packaging of viral RNA inside 
a capsid occurs [9]. Once the virion particles are mature 
they are released through lysis or exocytosis from 
the cell. Due to lack of knowledge about this new 
virus and lack of detailed insight about which proteins 
are involved in causing host cell disruption and over-
coming the host immune system, no particular treat-
ment is present for it.
3. Genetic diversity
SARS-CoV-2 was previously shown to be a close rel-
ative of SARS-CoV and their Receptor binding domain 
of S-proteins also resemble each other [15]. The known 
differences in proteins encoded by both viruses are pre-
sented in table I. The phylogenetic trees’ comparison 
has shown that SARS-CoV-2 is most closely related to 
the SARS-like bat viruses than human SARS-CoV [19]. 
Whole genome sequences of SARS-CoV-2 and corona-
virus of bats has shown 96% similarities [40].
The coronaviruses are the largest RNA viruses, 
with a genome size range of 26–32 kb [8]. A variable 
number of ORF (open reading frames), in the range of 
6 to 11, exists in the genome of the coronavirus. ORF’s 
are shown in figure 3. The 1st ORF, which is 67% of 
the whole genome, encodes 16 non-structural proteins. 
Genes for eight accessory proteins and four structural 
proteins are encoded at the 3’ terminus of RNA, while 
genes encoding orf1a and orf1b proteins (comprise 
non-structural proteins) are located at the 5’ terminus 
[15, 40]. There are five structural genes E, N, M, SM, 
and S, which encode envelope, nucleocapsid, mem-
brane glycoprotein, small membrane protein, and spike 
protein, respectively [32]. N-proteins of SARS-CoV 
and SARS-CoV-2 have a 90% similarity in sequences. 
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Fig. 2. General mode of replication of SARS-CoV. Starting with the attachment of viral S protein, present on the envelope, with ACE-2 
receptor on lung cells the viral RNA is released inside the cytoplasm through membrane fusion. Once inside the cell +ssRNA act as mRNA 
and the host ribosome will start making viral proteins (2 polyproteins and structural protein) which help viral genomic replication and 
capsid formation, after which packaging of viral RNA inside a capsid occurs. Once the virion particles are mature they are released through 
lysis or exocytosis.
Fig. 3. ORF’s of the genome of HB01 strain of SARS-CoV-2 (previously called 2019-nCoV) are shown.
Structural proteins are encoded at the 3’ terminus and non-structural at the 5’ terminus (Modified from [40]).
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The N-protein of SARS-CoV acts as a viral suppressor 
protein of RNAi, to overcome the host immunity. The 
N-protein of SARS-CoV-2 can also have the same effect 
[15, 34]. The functions of non-structural proteins (Nsp) 
of coronaviruses are mentioned in table 2, except Nsp 2 
and 11, whose functions are currently unknown. 
4. Transmission
The natural host reservoir for SARS-like coronavi-
ruses are reported to be bats, the intermediate host for 
the viruses are reported to be civets or camels and then 
they are transmitted to humans hence these viruses 
are capable of a host-species jump [16]. One of the 
major transmission routes of SARS-CoV-2 is human-
to-human transmission within close contact and has 
caused an exponential increase in the number of cases. 
Aerosol transmission happens when an infected per-
son coughs or sneezes shedding the virus in the air and 
touching inanimate objects infected with the virus are 
possible transmission routes [14, 17].
The current epidemic started when the earliest 
patients who went to Huanan seafood market in Wuhan 
city, Hubei province, China got infected with SARS-
CoV-2 after coming in contact with some animals; 
the intermediate animal source is yet to be confirmed. 
These infected patients became a source of infection for 
other healthy people [20]. Reportedly a large number 
of infected people did not have exposure to the seafood 
market so it is likely they got infected from the earli-
est patients hence person-to-person contact became 
a major reason for the spread of this epidemic [5]. The 
reason why coronavirus caused havoc throughout the 
world and became a cause of lockdown in multiple 
countries is its high transmission rate [3]. 
One recently published study indicated a  whole 
family of 6 was infected with this novel coronavi-
rus although none of the family members visited the 
Wuhan seafood market, only 2 persons of the family 
visited Wuhan hospital where they might have caught 
the virus from infected patients. From the two infected 
family members the whole family got infected. Real 
time RT-PCR was used to test the RNA extracted from 
patient samples with new coronavirus virus specific 
primers and probes [17]. The patients had symptoms 
such as fever, upper or lower respiratory tract infec-
tions however, older patients (> 60 years) showed more 
systemic symptoms [5]. 
A recent report suggested that the virus can also 
take an ocular route of transmission [18]. Vertical 
Table III
Different Vaccine Strategies with their Advantages and Disadvantages
 Easy preparation,
mRNA vaccines High Adaptability, High unstable under physiological conditions [24]
 Can induce strong immune responses
DNA vaccines Easy preparation Low immune responses [24]
 Neutralizing antibodies with high titer May induce toxicity with repeated doses
Viral vector vaccines Induces high humoral and cellular Pre-existing immunity will be a problem [11]
 immune responses
 Neutralizing antibodies with high titer, High cost
Subunit vaccines Induces high humoral and cellular Low immunity, [11]
 immune responses Repeated doses may require
Attenuated virus vaccines Quick development, Genotypic & phenotypic reversion possible [25]
 High immune responses
Inactivated virus vaccines Easy preparation, Not applicable for immunosuppressed individuals [25]
 Neutralizing antibodies with high titer
Vaccine strategy Advantages Disadvantages References
Nsp1 Degrade Cellular mRNA and constrain signaling of IFN
Nsp3 Blocking of host innate immune response and cut
 polypeptides 
Nsp4 Development of double membrane vesicles
Nsp5 Constrain IFN signaling and cleave polypeptides
Nsp6 Restrict expansion of auto phagosomes
Nsp7 Nsp8 and Nsp12 co-factor
Nsp8 Nsp7 and Nsp12 co-factor
Nsp9 Interact with RNA binding and dimerization
Nsp10 Nsp14 and Nsp16 support protein
Nsp12 Primer, which function depends upon Rd-Rp 
Nsp13 5 prime triphosphatase and RNA helicase
Nsp14 Exo ribonuclease activity
Nsp15 Exo ribonuclease activity
Nsp16 Regulate immune responses negatively and 2’‐O‐MTase
Table II
The functions of non-structural proteins in the replication
of coronaviruses are shown (Modified from [8])
Nsps Functions
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transmission is not found to be a route for this virus, 
as pregnant women with COVID-19 had virus nega-
tive newborns [6]. The best way suggested by the 
World Health Organization to limit the epidemic is by 
social distancing along with practicing good hygiene 
such as washing your hands regularly and wear pro-
tective masks.
5. Vaccination strategies against COVID-19
A study found a correlation between the universal 
BCG vaccine policy and reduced mortality and mor-
bidity ranges for COVID-19. They found that coun-
tries without a universal BCG vaccine policy were 
more adversely affected by the pandemic compared to 
Moderna DNA-based vaccines which Phase 3 starts in the 1st week          [4]
 code or a stabilized form of of July. It will include
 of SARS-CoV-2 spike protein the study of 30,000 patients
Curevac Lab-made RNA to spur the Begins the human trials https://www.curevac.com/en/covid-19/
 production of corona proteins
Inovio DNA-based vaccines Human trials to start https://www.inovio.com/our-focus-serving-patients/
  in later June covid-19/
Takis Biotech DNA-based vaccines Results of dose-response          [27]
  trials to be published in June
Zydus Cadila DNA-based vaccines Project is in pre-clinical https://zyduscadila.com/
  trials
Stemirna mRNA-based vaccines Clinical trials expected http://www.stemirna.com/en/index.aspx
Therapeutics  to start in Mid-April
Imperial College DNA-based vaccines Human trial started  https://www.imperial.ac.uk/covid-19-vaccine-trial/
London
Novavax Recombinant-protein Phase I/II started https://www.novavax.com/covid-19-coronavirus-
 nanoparticles derived from  in May 2020 vaccine-candidate-updates
 spike proteins of SARS-CoV-2
Vaxart Oral vaccine Phase I begins in the second https://vaxart.com/
  half of 2020
GlaxoSmithKline A protein-based vaccine Animal trials https://www.gsk.com/en-gb/media/press-releases/
(GSK) with the use of adjuvant  gsk-and-curevac-to-develop-next-generation-
   mrna-covid-19-vaccines/
University A protein-based candidate Animal trials https://www.vido.org/covid19/covid-19-news/
of Saskatchewan
Sanofi Recombinant DNA platform Phase 1 to be started https://www.sanofi.com/en/about-us/our-stories/
 swapping the part of corona- in the last quarter of 2020 sanofi-s-response-in-the-fight-against-covid-19
 virus with genetic material
 from a harmless virus
Geovax Labs/ Develop a live horsepox virus Pre-clinical stage https://www.geovax.com/news/geovax-progresses-
Bravovax which will be modified  in-coronavirus-covid-19-vaccine-development-
 to express protein fragments  program
 from SARS-CoV-2
Cansino Viral vector-based vaccine Phase II – All volunteers          [42]
Biologics  developed neutralizing 
  antibodies 
Greffex DNA-based vaccines:  Pre-clinical stage https://www.greffex.com
 Adenovirus based vector
 vaccines that involve
 a harmless virus that will
 express foreign genes like
 SARS-CoV-2 spike protein
Generex The firm uses insect cells Ex-Vivo Human Immune https://www.generex.com/covid-19
Biotechnology from fruit flies to produce System screening
 viral antigens of 33 Ii-Key-SARS-CoV-2
  peptides
Table IV
In process-Vaccines with its Candidates & Phase Trials
Manufacturer Vaccine candidate Phase trials [31] References
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countries having a universal BCG vaccine policy. They 
also found that BCG vaccination reduced the number 
of cases in a country [21].
6. In process vaccination strategies
 against COVID-19
Vaccines help the body enhance the immune 
response by triggering the generation of antibodies in 
addition to the development of T and B cells. Vaccines 
induce active immunity and provide immunological 
memory which enables the immune system to remem-
ber and respond rapidly in case of exposure. Vaccines 
often provide long-lasting immunity, but sometimes 
they don’t. Scientists at research institutes are working 
on the development of vaccines all over the world. Vac-
cine development can take a minimum of 18 months. 
7. Lack of antiviral treatment
 and antiviral treatment studies
In current times, there is no specific antiviral therapy 
to control this virus only supportive treatment for the 
coronavirus. Recombinant interferon only has a limited 
response with ribavirin against a coronavirus infection. 
The two viral protein inhibitors as an available option 
of treatment are Baricitinib (Janus and AAK1 kinases 
inhibitor) and Remdesivir (adenosine analog) [12]. 
The other antiviral drugs like chloroquine and 
hydroxychloroquine show an effective response against 
this virus. The drug chloroquine was first identified in 
1934 which is used against SARS-CoV infection, also 
used to treat other human diseases such as malaria, 
amoebiosis, HIV, and autoimmune diseases without 
any side effects. 
Leronlimab (CCR5 antagonist) and Galidesivir 
(nucleoside RNA-polymerase inhibitor) are other pos-
sible treatment options [34]. According to guidelines, 
Interferon-alpha (IFN-alpha) and lopinavir-ritonavir 
(combined therapy) are recommended antivirals. Chi-
nese medicines, tested to treat influenza H1N1, such as 
Lianhua Qingwen and ShuFeng Jiedu capsules are also 
tested against SARS-CoV-2 [7, 18].
The compounds tryptanthrin and indigodole B 
extracted from the plant Strobilanthes cusia, can reduce 
the cytopathic effects of human coronavirus NL63. 
S. cusia has also been used to treat SARS-CoV. The 
spikes of NL63 and SARS-CoV-2 are genetically iden-
tical. Hence, S. cusia can also be a treatment option for 
SARS-CoV-2 [33].
Recuperating patients’ plasma and antibodies are 
proposed for treatment. Some vaccine strategies are 
assessed in animals, including recombinant proteins, 
DNA vaccines, live and killed attenuated vaccines, and 
subunit vaccines [6].
8. Precautions
As the virus spread increases with each passing day 
we have to minimize the transmission cycle by follow-
ing the different precautionary measures as suggested 
by the World Health Organization: 
• Avoid contact with suspected people.
• Ensure social and physical distancing to prevent 
the transmission of disease.
• Use of protective surgical masks in public.
• Proper hand washing with sanitizer after every ten 
minutes.
• Use a mask at all times within an airport facility 
and outside while traveling.
• Avoid crowded places.
• Avoid contact with unwell people (having flu or 
cough like symptoms).
• Avoid traveling overseas.
• Ensure good hygiene (wash hand frequently with 
soap).
• Avoid eating raw or undercooked meat of any 
type.
• Avoid contact with animals.
9. Conclusion
Coronaviruses are +ssRNA viruses with 7 human 
coronaviruses, they mainly affect the respiratory sys-
tem. Group B coronaviruses are the main concern for 
researchers as it includes the causative virus of the 
SARS-CoV-2 epidemic. This virus has a high patho-
genicity and high virulence rate [41]. SARS-CoV-2 has 
now spread all around the Globe and is declared a pub-
lic health emergency by WHO. Its sequence was found 
to be 96% similar to coronaviruses found in bats [43]. 
The high transmission rate of the virus is the main 
concern. Research has been conducted to find effec-
tive measures in controlling the speed of the disease 
with one study reported to minimize person-to-person 
contact rate to 30% [35]. Real Time Polymerase chain 
reaction (PCR) with new coronavirus virus-specific 
primers and probes is the main diagnostic test used to 
test RNA extracted from a patient [17]. 
The most commonly reported clinical manifesta-
tions are fever, cough, fatigue, and pneumonia. Patients 
with mild cases recover early, mostly after one week, 
while serious cases lead to alveolar damage which 
causes progressive respiratory failure and ultimately 
leads to death [1]. The genomic nature of this virus is 
single-stranded RNA which makes it harder to develop 
vaccines and yet no approved vaccine exists. 
Many research groups around the world are work-
ing to make vaccines and antivirals as explained in the 
vaccination and antiviral section above. Some antivirals 
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that have shown in-vitro results against novel corona-
virus include chloroquine and remdesivir [36] but the 
virus has error-prone RNA dependent RNA polymer-
ases that are responsible for mutations and recombina-
tion events which are of major concern.
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